The DOI matches its Crossref record; 55 of the 58 references it cites were found in a registry or an index.
Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models
Open accessAbstract
High-grade serous ovarian carcinoma presents significant clinical and therapeutic challenges. Although the traditional model of carcinogenesis has focused on the ovary as a tumor initiation site, recent studies suggest that there may be additional sites of origin outside the ovary, namely the secretory cells of the fallopian tube. Our study demonstrates that high-grade serous tumors can originate in fallopian tubal secretory epithelial cells and also establishes serous tubal intraepithelial carcinoma as the precursor lesion to high-grade serous ovarian and peritoneal carcinomas in animal models targeting the Brca, Tp53, and Pten genes. These findings offer an avenue to address clinically important questions that are critical for cancer prevention and early detection in women carrying BRCA1 and BRCA2 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conditional knockout mice, using the Cre-lox system for cell type specificity, have been used to reproduce oncogenic mutations and HR defects to study ovarian cancer development and responses to clinically relevant treatments such as platin-based drugs and PARPis (Szabova et al., 2012; Perets et al., 2013; Szabova et al., 2014; Zhai et al., 2017).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Perets et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Generalized lacZ expression with the ROSA26 Cre reporter strain
Soriano, P. (1999) · Nature Genetics · doi:10.1038/5007 · Cited by 5,237
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
Alsop, K., Fereday, S., Meldrum, C. J., DeFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C. J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,204
Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C. M., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,114
Jonkers, J., Meuwissen, R. L. J., van der Gulden, H. M. L., Peterse, H. L., van der Valk, M., & Berns, A. J. M. (2001) · Nature Genetics · doi:10.1038/ng747 · Cited by 1,044
Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C. M., Garber, J. E., Cramer, D. W., & Crum, C. P. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000180854.28831.77 · Cited by 913
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Lee, Y., Miron, A., Drapkin, R., Nucci, M. R., Medeiros, F., Saleemuddin, A., Garber, J. E., Birch, C., Mou, H., Gordon, R., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2091 · Cited by 904
Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers
Mutter, G. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.924 · Cited by 829
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R. N., Stewart, C. J. R., Fereday, S., Caldas, C., DeFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 815
Xu, X., Wagner, K., Larson, D. M., Ohler, Z. W., Li, C., Ried, T., Hennighausen, L. G., Wynshaw-Boris, A. J., & Deng, C. (1999) · Nature Genetics · doi:10.1038/8743 · Cited by 766
Dinulescu, D. M., Ince, T. A., Quade, B. J., Shafer, S. A., Crowley, D. G., & Jacks, T. (2004) · Nature Medicine · doi:10.1038/nm1173 · Cited by 601
Early restriction of peripheral and proximal cell lineages during formation of the lung
Perl, A. T., Wert, S. E., Nagy, A., Lobe, C. G., & Whitsett, J. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152238499 · Cited by 525
Gewinner, C. A., Wang, Z. C., Richardson, A. L., Teruya‐Feldstein, J., Etemadmoghadam, D., Bowtell, D. D. L., Barretina, J., Lin, W. M., Rameh, L. E., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 466
A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors
Laury, A., Perets, R., Piao, H.-Y., Krane, J., Barletta, J., French, C., Chirieac, L., Lis, R., Loda, M., Hornick, J., et al. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318216c112 · Cited by 429
Cheung, H. W., Cowley, G. S., Weir, B. A., Boehm, J. S., Rusin, S., Scott, J. A., East, A., Ali, L. D., Lizotte, P. H., Wong, T. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109363108 · Cited by 423
New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Levanon, K., Crum, C., & Drapkin, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1107 · Cited by 412
Self-citationAre All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?
Przybycin, C. G., Kurman, R. J., Ronnett, B. M., Shih, I., & VANG, R. S. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181ef7b16 · Cited by 410
High-grade serous ovarian cancer arises from fallopian tube in a mouse model
Kim, J., Coffey, D. M., Creighton, C. J., Yu, Z., Hawkins, S. M., & Matzuk, M. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117135109 · Cited by 400
Cre/loxP‐mediated inactivation of the murine Pten tumor suppressor gene
Lesche, R., Groszer, M., Gao, J., Wang, Y., Messing, A., Sun, H., Liu, X., & Wu, H. (2002) · genesis · doi:10.1002/gene.10036 · Cited by 387
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
Nichols, K. E., Malkin, D. M., Garber, J. E., Fraumeni, J. F., & Li, F. P. (2001) · PubMed · Cited by 356
Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche
Flesken‐Nikitin, A., Hwang, C., Cheng, C.-Y., Michurina, T. V., Enikolopov, G., & Nikitin, A. Y. (2013) · Nature · doi:10.1038/nature11979 · Cited by 352
WU, R. T., Hendrix, N. D., Kuick, R. D., Zhai, Y., Schwartz, D. R., Akyol, A., Hanash, S., Misek, D. E., Katabuchi, H., Williams, B. O., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.016 · Cited by 312
Traykova-Brauch, M., Schönig, K., Greiner, O., Miloud, T., Jauch, A., Bode, M., Felsher, D., Glick, A., Kwiatkowski, D., Bujard, H., et al. (2008) · Nature Medicine · doi:10.1038/nm.1865 · Cited by 297
Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
Leeper, K., Garcia, R., Swisher, E., Goff, B., Greer, B., & Paley, P. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6779 · Cited by 295
Folkins, A. K., Jarboe, E. A., Saleemuddin, A., Lee, Y., Callahan, M. J., Drapkin, R., Garber, J. E., Muto, M. G., Tworoger, S. S., & Crum, C. P. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.012 · Cited by 292
Modeling High-Grade Serous Ovarian Carcinogenesis from the Fallopian Tube
Karst, A. M., Levanon, K., & Drapkin, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017300108 · Cited by 280
Self-citationFlesken‐Nikitin, A., Choi, K., Eng, J. P., Shmidt, E. N., & Nikitin, A. Y. (2003) · PubMed · Cited by 271
Eppig, J. T., Blake, J. A., Bult, C. J., Kadin, J. A., Richardson, J. E., & the Mouse Genome Database Group (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr974 · Cited by 243
Expression of PAX8 in Normal and Neoplastic Tissues
Tacha, D., Zhou, D., & Cheng, L. (2011) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e3182025f66 · Cited by 231
PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma
Laury, A. R., Hornick, J. L., Perets, R., Krane, J. F., Corson, J. M., Drapkin, R., & Hirsch, M. S. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181da7687 · Cited by 229
Kinross, K. M., Montgomery, K. G., Kleinschmidt, M., Waring, P., Ivetac, I., Tikoo, A., Saad, M., Hare, L., Roh, V., Mantamadiotis, T., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59309 · Cited by 215
Status of Tumor Markers in Ovarian Cancer Screening
Bast, R. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.068 · Cited by 205
Emerging roles for PAX8 in ovarian cancer and endosalpingeal development
Bowen, N. J., Logani, S., Dickerson, E. B., Kapa, L. B., Akhtar, M., Benigno, B. B., & McDonald, J. F. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.08.052 · Cited by 199
Veeck, J., Ropero, S., Setién, F., González‐Suárez, E., Osório, A., Benitez, J. J., Herman, J. G., & Esteller, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1010 · Cited by 173
Mittag, J., Winterhager, E., Bauer, K., & Grümmer, R. (2006) · Endocrinology · doi:10.1210/en.2006-1054 · Cited by 127
High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression
Roh, M. H., Yassin, Y., Miron, A., Mehra, K. K., Mehrad, M., Monte, N. M., Mutter, G. L., Nucci, M. R., Ning, G., McKeon, F., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.119 · Cited by 123
Szabova, L., Yin, C., Bupp, S., Guerin, T. M., Schlomer, J. J., Householder, D. B., Baran, M. L., Yi, M., Song, Y., Sun, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3834 · Cited by 122
Karst, A. M., Levanon, K., Duraisamy, S., Liu, J. F., Hirsch, M. S., Hecht, J. L., & Drapkin, R. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.05.021 · Cited by 92
Distant metastases in ovarian cancer: association with p53 mutations.
Sood, A. K., Sorosky, J. I., Dolan, M., Anderson, B., & Buller, R. E. (1999) · PubMed · Cited by 84
Clark-Knowles, K. V., Garson, K., Jonkers, J., & Vanderhyden, B. C. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.09.026 · Cited by 76
Mullany, L. K., Fan, H.-Y., Liu, Z., White, L. D., Marshall, A. N., Gunaratne, P. H., Anderson, M. L., Creighton, C. J., Xin, L., Deavers, M. T., et al. (2011) · Oncogene · doi:10.1038/onc.2011.70 · Cited by 73
Molecular Requirements for Transformation of Fallopian Tube Epithelial Cells into Serous Carcinoma
Jazaeri, A. A., Bryant, J. L., Park, H., Li, H., Dahiya, N., Stoler, M. H., Ferriss, J. S., & Dutta, A. (2011) · Neoplasia · doi:10.1593/neo.11138 · Cited by 71
Clark-Knowles, K. V., Senterman, M. K., Collins, O. M., & Vanderhyden, B. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008534 · Cited by 61
Type I to Type II Ovarian Carcinoma Progression
WU, R. T., Baker, S. J., Hu, T. C., Norman, K. M., Fearon, E. R., & Cho, K. R. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.12.031 · Cited by 56
Phosphoinositide 3‐kinase and INPP4B in human breast cancer
Bertucci, M. C., & Mitchell, C. A. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12036 · Cited by 54
Induction of Ovarian Leiomyosarcomas in Mice by Conditional Inactivation of Brca1 and p53
Quinn, B. A., Brake, T., Xiang, H., Baxter-Jones, K., Litwin, S., Ellenson, L. H., & Connolly, D. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008404 · Cited by 46
Early Telomere Shortening and Genomic Instability in Tubo-Ovarian Preneoplastic Lesions
Chene, G., Tchirkov, A., Eymard-Pierre, É., Dauplat, J., Raoelfils, I., Cayre, A., Watkin, E., Vago, P., & Penault-Llorca, F. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3947 · Cited by 44
Kuhn, E., Meeker, A. K., Visvanathan, K., Gross, A. L., Wang, T., Kurman, R. J., & Shih, I. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.67 · Cited by 34
The tubal hypothesis of ovarian cancer: caution needed
Collins, I. M., Domchek, S. M., Huntsman, D. D., & Mitchell, G. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70222-4 · Cited by 31
Flagged first, then by citations
3 of the 58 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D. L., Böhm, S., Ahmed, A. A., Aspuria, P.-J. P., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S. P., Bookman, M. A., et al. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4019 · Cited by 1,395
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Narayanan, J., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01865-0 · Cited by 1,132
The Dualistic Model of Ovarian Carcinogenesis
Kurman, R. J., & Shih, I. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 972
High grade serous ovarian carcinomas originate in the fallopian tube
Labidi‐Galy, S. I., Papp, E., Hallberg, D. L., Niknafs, N., Adleff, V., Noë, M., Bhattacharya, R., Novak, M., Jones, S., Phallen, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00962-1 · Cited by 762
Metadata
- Authors
- Perets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., Chen, J. Y. H., Ohman, A. W., Stepule, C. D., Kwak, S., Karst, A. M., Hirsch, M. S., Setlur, S. R., Crum, C. P., Dinulescu, D. M., & Drapkin, R.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Dinulescu, Daniela M.
- Drapkin, Ronny
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 24
- Issue
- 6
- Pages
- 751-765
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3917315
- OpenAlex
- W2013107316
- Cited by
- 596
- References
- 58
- Citations by year
- 2026: 23 · 2025: 49 · 2024: 35 · 2023: 47 · 2022: 47 · 2021: 46 · 2020: 85 · 2019: 44 · 2018: 42 · 2017: 44 · 2016: 51 · 2015: 49 · 2014: 32
- FWCI
- 52.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust
- National Institutes of Health
- National Cancer Institute (R21CA156021, U01CA152990, P50CA105009)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- high-grade serous ovarian cancer, serous tubal intraepithelial carcinoma, cancer of unknown primary, BRCA1, BRCA2, TP53, PTEN, peritoneal cancer, precursor lesions, cancer prevention, early detection
- MeSH terms
- PAX8 Transcription Factor, Animals, Cell Transformation, Neoplastic, Epithelium, Fallopian Tube Neoplasms, Female, Mice, Inbred C57BL, Ovarian Neoplasms, Precancerous Conditions, Genes, p53, Cystadenocarcinoma, Serous, Genes, BRCA1, Integrases, Genes, BRCA2, PTEN Phosphohydrolase, Mice, Paired Box Transcription Factors, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
